Therapeutic effects with Hibiscus sabdariffa Linn. (Roselle) extract supplementation on arterial stiffness and other cardiovascular risk parameters in patients with psoriasis

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250616018

Enrollment

Registered

2025-06-16

Start date

2023-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arterial stiffness and other cardiovascular risk in patients with psoriasis Hibiscus sabdariffa Linn. extract, psoriasis, arterial stiffness, cardiovascular risk

Interventions

Hibiscus sabdariffa Linn extract 3000 milligrams per day via oral for 12 weeks

Experimental Dietary Supplement

Hibiscus sabdariffa Linn extract

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. age 18-60 years 2. Diagnosis with Psoriasis 3. Can follow up at week 4,8,12 4. Sign Consent form

Exclusion criteria

Exclusion criteria: 1.Pregnant 2.Acute illness : infection, fever 3.Cancer 4.History of Drugs use : Pseudoephedrine, Hydrochlorothiazide 5.History of Cardiovascular disease, Stroke, Chronic kidney disease 6.Allergy to Hibiscus sabdariffa L. extract 7.Cannot follow up

Design outcomes

Primary

Measure	Time frame
Arterial stiffness at 4,8,12 weeks after first treatment Cardio Ankle Vascular Index	—

Secondary

Measure	Time frame
Body weight at 4,8,12 weeks after first treatment weighing scale,body mass index at 4,8,12 weeks after first treatment weighing scale, calculate,Waist circumference at 4,8,12 weeks after first treatment tape measure,Hip circumference at 4,8,12 weeks after first treatment tape measure,Waist-Hip ratio at 4,8,12 weeks after first treatment tape measure, calculate,systolic/diastolic blood pressure at 4,8,12 weeks after first treatment Sphygmomanometer,fasting blood sugar at 12 weeks after first treatment laboratory blood test,Hemoglobin A1c at 12 weeks after first treatment laboratory blood test,Lipid profile at 12 weeks after first treatment laboratory blood test ,creatinine at 12 weeks after first treatment laboratory blood test ,Glomerular Filtration Rate at 12 weeks after first treatment laboratory blood test ,high sensitivity C-reactive protein at 12 weeks after first treatment laboratory blood test,Aspartate Transaminase at 12 weeks after first treatment laboratory blood test ,Alanine Aminotransferase at 12 weeks after first treatment laboratory blood test	—

Measure

Time frame

Body weight at 4,8,12 weeks after first treatment weighing scale,body mass index at 4,8,12 weeks after first treatment weighing scale, calculate,Waist circumference at 4,8,12 weeks after first treatment tape measure,Hip circumference at 4,8,12 weeks after first treatment tape measure,Waist-Hip ratio at 4,8,12 weeks after first treatment tape measure, calculate,systolic/diastolic blood pressure at 4,8,12 weeks after first treatment Sphygmomanometer,fasting blood sugar at 12 weeks after first treatment laboratory blood test,Hemoglobin A1c at 12 weeks after first treatment laboratory blood test,Lipid profile at 12 weeks after first treatment laboratory blood test ,creatinine at 12 weeks after first treatment laboratory blood test ,Glomerular Filtration Rate at 12 weeks after first treatment laboratory blood test ,high sensitivity C-reactive protein at 12 weeks after first treatment laboratory blood test,Aspartate Transaminase at 12 weeks after first treatment laboratory blood test ,Alanine Aminotransferase at 12 weeks after first treatment laboratory blood test

—

Countries

Thailand

Contacts

Public ContactThansinee Ounhasuttiyanon

Mae Fah Luang University

aomm.thansinee@gmail.com0889656195

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026